Masitinib (AB Science) is an oral tyrosine kinase inhibitor being developed by AB Science. It targets a number of receptor tyrosine kinases including c-Kit, fibroblast growth factor receptor 3, platelet-derived growth factor receptor alpha/beta, lymphocyte-specific protein tyrosine kinase (Lck), Lck/Yes-related novel protein tyrosine kinase, and focal adhesion kinase.
This makes the drug effective at controlling the survival, differentiation, and degranulation of mast cells, which are involved in oncogenic processes such as angiogenesis, tissue remodeling, and immunomodulation.
- masitinib: Prostate cancer
- masitinib: Colorectal cancer (CRC)
- masitinib: Asthma
- masitinib: Pancreatic cancer
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/t7nx98/2018_masitinib?w=4